Breye Therapeutics
Breye Therapeutics develops oral medicines for retinal diseases, with a focus on diabetic retinopathy and age-related macular degeneration.
$76.65M Series A ·
Led by Mission BioCapital · Source: european-biotechnology.com
Total raised: $80.77M across 2 sourced rounds
All 2 rounds ↓Signals
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | $76.65M | european-biotechnology.com | ||
| Seed | $4.12M | finsmes.com |
Timeline
- Website created
Founders and team
UM
Ulrik Mouritzen Founder
Investors
CCatalyze Capital
EExport and Investment Fund
IInnovestor
MMission BioCapitallead investor
MModi Ventures
NNovo Holdingslead investor
PPappas Capital
SSound Bioventureslead investor
- TThe Ljungstrom Family Office
VVaekstfonden
Companies like Breye Therapeutics
NNewLimit$435M Series B+ · Jun 2026
TTune Therapeutics$175M Series B+ · Jan 2025
FFive Alarm BioSeed · Feb 2023LLyora Therapeutics$2.5M Seed · Jul 2026
RRgenta TherapeuticsSeries B+ · Nov 2026
AAddition Therapeutics$100M Series A · Dec 2025
Other companies backed by Mission BioCapital
OOyster Therapeutics$60M Series A · Nov 2026
DDren Bio$350M Series B+ · Oct 2026CCloverleaf Bio$33M Seed · Sep 2026
MMediar Therapeutics$76M Series B+ · Jan 2026
AAI Proteins$41.5M Series A · Nov 2025
GGlycomine$115M Series B+ · May 2025
Mission BioCapital portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/breye-therapeutics (get a free API key).